Isturisa Treatment in Mild Autonomous Cortisol Secretion( MACS)

Recruiting now · Phase 4

Conditions studied: Mild Autonomous Cortisol Secretion (MACS)

In brief

To characterize the impact of Isturisa on clinical features and comorbidities associated with MACS. The investigators hypothesize that patients treated with Isturisa will exhibit significantly better metabolic indicators (such as fasting glucose, HbA1c, and lipid profile), blood pressure, weight, body composition and bone mineral density than at Baseline. The investigators also assess the effect of Isturisa on quality of life and psychological symptoms in patients with MACS. The investigators hypothesize that treatment with Isturisa will lead to significant improvements in quality-of-life scores and reductions in depression scores compared to Baseline.

Key facts

Study ID
NCT07247058
Run by
Johns Hopkins University
People needed
10
Starts
2026-02-02
Expected to finish
2029-03-01
Last updated by the study team
2026-03-05

Who can join

Age: 18 and older. Sex: any. Healthy volunteers: not accepted.

You may qualify if…

You may not qualify if…

Where it is running

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.